Sorafenib Gastric Cancer Asian Phase I Study

NCT00663741 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

13

Enrollment

INDUSTRY

Sponsor class

Conditions

Gastric Cancer

Interventions

DRUG: Sorafenib (Nexavar, BAY43-9006)
DRUG: Sorafenib (Nexavar, BAY43-9006)
DRUG: Sorafenib (Nexavar, BAY43-9006)

Sponsor

Bayer